KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Adaptive Biotechnologies (ADPT) Gross Margin (2018 - 2025)

Adaptive Biotechnologies (ADPT) has disclosed Gross Margin for 8 consecutive years, with 42.19% as the latest value for Q4 2025.

  • Quarterly Gross Margin fell 1978.0% to 42.19% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 65.86% through Dec 2025, up 852.0% year-over-year, with the annual reading at 65.86% for FY2025, 613.0% up from the prior year.
  • Gross Margin hit 42.19% in Q4 2025 for Adaptive Biotechnologies, down from 80.68% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 80.68% in Q3 2025 to a low of 210.03% in Q2 2023.
  • Historically, Gross Margin has averaged 39.09% across 5 years, with a median of 58.63% in 2024.
  • Biggest five-year swings in Gross Margin: plummeted -27974bps in 2023 and later skyrocketed 26530bps in 2024.
  • Year by year, Gross Margin stood at 59.56% in 2021, then skyrocketed by 217bps to 69.95% in 2022, then plummeted by -59bps to 28.7% in 2023, then surged by 116bps to 61.98% in 2024, then plummeted by -32bps to 42.19% in 2025.
  • Business Quant data shows Gross Margin for ADPT at 42.19% in Q4 2025, 80.68% in Q3 2025, and 69.43% in Q2 2025.